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Abstract
Bloodstream infection (BSI) is associated with major morbidity and mortality. Population-based studies are the optimal designs to determine
the occurrence of BSI. This is because in these designs all cases of BSI occurring in residents of a defined population are included, and where
the population at risk is known incidence rates may be determined. Furthermore, selection bias is minimized by inclusion of all cases fulfilling
the case definition. Despite the methodological advantages, there is only a small body of published literature investigating BSI at the
population level. Few studies conducted since the 1970s have included all aetiologies of BSI and have reported rates between 80 and 189 per
100 000 per year with higher rates reported in more recent years. The three most common aetiologies of BSI are Escherichia coli,
Staphylococcus aureus and Streptococcus pneumoniae, which occur at approximate rates of 35, 25 and 10 per 100 000 population, respectively.
The incidence of BSI has been demonstrated to vary significantly among regions, and this is in part related to blood culturing rates,
population demographic differences and risk factor distribution in regions. Knowledge of the incidence of BSI is important for setting
healthcare and research priorities and for evaluating the effectiveness of preventative interventions.
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Introduction
Bloodstream infection (BSI) is associated with major morbidity
and mortality worldwide [1–8]. The terms bacteraemia and BSI
are frequently used interchangeably and generally refer to the
growth of a microorganism from a blood culture obtained
from a patient with clinical signs of infection and where
contamination has been ruled out. These infections are often
classified as primary (no focus) or secondary when associated
with clinical or microbiological confirmation of infection at a
defined body site. In addition, they have been further
traditionally classified as either hospital-acquired or commu-
nity-acquired. However, it is now widely accepted that a third
category of healthcare-associated BSI be recognized among
patients who have community-onset BSI and significant recent
healthcare system exposure [9–11].
Population-based studies have been proposed as the best
way of defining the epidemiology of infectious diseases. In
these designs, all cases of disease occurring among residents of
a defined geographical area are ascertained. This is an
important aspect, as studies conducted in selected patients,
such as in a given clinic or emergency department or among
those who are admitted to a hospital or arbitrary selection of
hospitals, risk significant selection bias [12,13]. Another key
feature of population-based studies is that the population at
risk is definable. As a result, incidence rates can be determined
and may be standardized against a reference population. These
may then be used to establish the burden of a disease and
facilitate comparison among different regions and time periods.
The objective of this report was to review population-based
studies investigating the incidence of BSI and examine regional
and temporal differences and trends.
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Population-based Studies of BSI Incidence
Articles published in English were initially searched for
potential inclusion in this report by performing a Medline
search through the PubMed interface using the terms ‘popu-
lation’ and ‘bacteraemia’ or ‘bloodstream infection’. Abstracts
were screened and full-length articles were retrieved as
appropriate. Bibliographies were reviewed in selected studies
and the author’s personal files were reviewed for further
potential studies. Specifically in the first case, population-based
studies investigating the incidence all BSI in non-selected
populations were sought. In the second case, studies specif-
ically investigating the incidence of the three most common
aetiologies of Escherichia coli, Staphylococcus aureus and Strep-
tococcus pneumoniae were retrieved.
Overall populations
There have been few studies that have investigated the overall
incidence of BSIs in entire populations [4,6–8,14]. The first was
reported by Filice et al. [7] among residents of Charleston
County, SC, USA (population c.250 000) during 1974–76. All
common potential blood culture contaminants including coag-
ulase negative staphylococci (CONS) were excluded. They
identified 291 cases for an incidence of 80 per 100 000
annually. Of these, 181 cases (42 per 100 000) were commu-
nity-acquired, 83 cases (31 per 100 000) were nosocomial, and
27 cases were unclassified. Eight cases (3.2 per 100 000) were
polymicrobial. The most common isolates were E. coli,
S. aureus and Klebsiella spp. with rates of 19, 9.7 and 8.9 per
100 000 population, respectively.
Sjoberg and Fredlund [15] reported on all blood cultures in
the County of Orebo, Sweden (population 270 000) during
1980–86. They identified 4057 isolates, which corresponded to
an annual incidence of 215 isolates per 100 000 population. The
most common isolates were E. coli (52.9 per 100 000), S. aureus
(36.3 per 100 000), coagulase-negative staphylococci (22.6 per
100 000) and Streptococcus pneumoniae (12.2 per 100 000). It is
important to note that in this study, non-residents of the region
were not excluded and that the unit of analysis was isolates and
not episodes of infection. As a result, the true incidence of
episodes of BSI in their region was undoubtedly lower than the
reported rate of 215 per 100 000.
Madsen et al. [4] investigated the incidence of bacteraemia
in North Jutland County Denmark (population 483 911)
during 1981–94. Among the nearly 7 million person-years of
observation, 7198 episodes were diagnosed for an incidence of
106 per 100 000 population. The most common isolates were
E. coli (32 per 100 000), S. aureus (18 per 100 000) and
Streptococcus pneumoniae (incidence not reported). They found
that the overall rate increased from 76 per 100 000 in 1981 to
153 per 100 000 in 1994 and that this was associated with
both larger volume of blood draw and with increased blood
culturing rates in later years.
Skogberg et al. reported on national BSI surveillance data
from Finland (population 5.2 million) during 1995–2002 [8]
and subsequently during 2004–07 [16]. The first and second
studies identified 51 510 and 33 473 cases for overall
incidences of 125 and 159 per 100 000 annually, respectively.
The most common organisms isolated were (1995–2002 and
2004–07 incidence rates estimated from report data): E. coli
(30 and 43 per 100 000), S. aureus (16 and 21 per 100 000),
CONS (16 and 16 per 100 000) and Streptococcus pneumo-
niae (12 and 14 per 100 000). They observed annual
increases of 4.5% and 4.4% in the first and second studies
and these were associated with increases in blood culture
sampling rates.
Uslan et al. [6] investigated BSIs in Olmsted County, MN,
USA during 2003–05 (population 124 277) and age-adjusted
and gender-adjusted the rates to the 2000 US population. They
found 650 cases for an overall incidence rate of 189 per
100 000 of which 124 (19%) cases were nosocomial, 237
(37%) cases were healthcare-associated, and 289 (44%) cases
were community-acquired. Seventy-five (7%) cases were
polymicrobial in aetiology. The most common isolates were
E. coli at 48 per 100 000 and S. aureus at 32 per 100 000.
These were followed in frequency by CONS and Klebsiella
species (incidence rates not reported).
Sogaard et al. [14] reported on the population incidence of
bacteraemia in Northern Denmark between 1992 and 2006. In
all, 11 703 episodes were identified in the half million
population for an overall average annual incidence of 153 per
100 000 per year. Rates increased significantly over time with
observed incidences of 114 per 100 000 in 1992 and 166 per
100 000 in 2006. Overall, the proportions of community-
acquired, nosocomial and healthcare-associated BSI were 51,
39 and 17%, respectively. However, there was a significant
change over time with a proportional shift to increased
incidence of healthcare-associated bacteraemia. The most
common aetiologies were E. coli, S. aureus and Streptococcus
pneumoniae.
Wilson et al. [17] reported on population-based surveil-
lance for all bacteraemias identified at 167 laboratories (95% of
all laboratories) in England (population 51 million) in 2008.
They identified 97 195 episodes for an incidence of 189 per
100 000 population. The most common aetiologies were
E. coli, CONS and S. aureus with rates of 43, 32 and 22 per
100 000, respectively.
A number of other studies have investigated all episodes of
BSI occurring in populations but have either presented limited
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data, restricted the report to certain subpopulations, or have
had other potentially significant limitations. A number of these
studies are further discussed below.
Douglas et al. [18] studied all episodes of clinically significant
bacteraemia identified at the Royal Darwin Hospital, the major
hospital serving the c.100 000 residents of the north of the
Northern Territory of Australia. It is not clear based on
reported methods whether this study was population-based
and completely ascertained all cases of BSI occurring among
residents of the region and excluded all cases among non-
residents. However, these authors found 257 patients with
bacteraemia during a 12-month period (suggesting an incidence
rate of 257 per 100 000). The most common aetiologies were
S. aureus (methicillin-susceptible S. aureus 54 cases; methicillin-
resistant S. aureus (MRSA) 19 cases), E. coli (48 cases) and
CONS (30 cases). A remarkably high rate of Burkholderia
pseudomallei (16 cases) BSI was also noted.
In another study, Einsiedal and Woodman [19] investigated
BSI in central Australia during 2001–05 with a focus on risk
between Aboriginal and non-Aboriginal adults. They observed
an overall rate of BSI (adults and children) of 1098 per 100 000
in Aboriginals compared with 67.7 per 100 000 in non-
Aboriginals (relative risk 16.2; 95% CI 12.9–20.3). While an
overall population-based rate was not reported, based on data
presented this is estimated at a remarkable 454 per 100 000.
The most common aetiologies were E. coli, S. aureus and
Streptococcus pneumoniae (specific incidence rates not avail-
able).
Reacher et al. [20] described all bacteraemia cases reported
from laboratories in England and Wales between 1990 and
1998. From a methodological perspective it is important to
note that not all laboratories in these regions participated and
audits for completeness of ascertainment of cases were not
specified. However, by the final year of the study, 208/229
(91%) of the laboratories participated. The overall incidence in
1998 was c.95 per 100 000 (calculated from data in the
report). The most common aetiologies were E. coli, S. aureus,
CONS and Streptococcus pneumoniae.
Population-based studies investigating all community-onset
BSIs in two different regions in Canada have been reported
[5,21]. In the first [5], all community-onset BSI in the Calgary
area (population 1 million) between 2000 and 2004 were
included and the overall incidence was 81.6 per 100 000. In the
second study, conducted in the Victoria area during 1998–
2005, the incidence was 101.2 per 100 000 [21]. In both
studies the most common aetiologies were E. coli, S. aureus
and Streptococcus pneumoniae. It is notable that the Calgary
study excluded all potential contaminants such as CONS
(thereby potentially underestimating the true incidence of BSI)
and that these two populations vary in their demographic
profiles. After age and gender standardization against the
Calgary population and exclusion of CONS, the overall
Victoria incidence rate was lower at 69 per 100 000 [21].
Specific aetiologies
Several studies, most commonly from relatively few centres in
Australia, Canada, Denmark, Finland, Iceland, New Zealand,
Sweden and the USA, have investigated the population-based
epidemiology of specific aetiologies of BSI in non-selected
populations. Escherichia coli, S. aureus and Streptococcus pneumo-
niae represent the most common aetiologies of BSI and typically
account for one-half or more of all BSIs and are therefore
specifically reviewed in further detail in the following sections.
Escherichia coli. Escherichia coli has consistently been the most
frequent cause of BSI in population-based studies; with
approximate incidence rates of 19 per 100 000 in Charleston
County, SC, USA in 1974–76 [7], 53 per 100 000 in Orebo
Sweden during 1980–86 [15], 32 per 100 000 in North Jutland
Denmark during 1981–94 [4], 30 per 100 000 during 1995–
2002 [8] and 43 per 100 000 during 2004–07 [16] in Finland,
40 per 100 000 in Olmsted County, MN, USA during 2003–05
[6], and 43 per 100 000 in England in 2008 [17]. However,
there has been a relative paucity of individual population-based
studies specifically investigating the epidemiology of E. coli BSI.
Kennedy et al. [22] reported on E. coli bacteraemia in the
Canberra area (population 366 000) during 2000–04. They
identified 515 episodes among area residents for an annual
incidence of 28 per 100 000 population. Of these, 68% were
community-acquired, 13% were healthcare-associated and 19%
were nosocomial. Resistance was common to ampicillin,
amoxicillin-clavulanate, cotrimoxazole and cephalothin but
rare to gentamicin, ciprofloxacin and cefotaxime.
Laupland et al. [23] conducted population-based surveil-
lance for E. coli BSI in the Calgary, Canada area during 2000–06
and identified an overall annual population incidence of 30.3/
100 000. Among these cases 15% were nosocomial, 32% were
healthcare-associated and 53% were community-acquired.
During the 7 years of the study, rates of resistance increased
to all standard antimicrobials tested except imipenem,
co-trimoxazole and piperacillin–tazobactam.
Al-Hasan et al. [24] reported on E. coli BSI from Olmsted
County, MN, USA (population 124 277) during 1998–2007.
They identified 461 cases overall for an incidence of 41.4 per
100 000 and reported age-adjusted incidence rates of 48 and
34 per 100 000 for females and males, respectively. Among all
cases, 59% were community-acquired, 32% were healthcare-
associated and 9% were nosocomial. Resistance rates
increased significantly to ampicillin, ampicillin/sulbactam, co-
trimoxazole and ciprofloxacin but not to carbapenems,
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cephalosporins and piperacillin/tazobactam during the study
period.
Staphylococcus aureus. Staphylococcus aureus is the second most
frequent pathogen implicated as a cause of BSI in population-
based studies investigating overall incidence with rates of 10
per 100 000 in Charleston County, SC, USA in 1974–76 [7],
36 per 100 000 in Orebo County Sweden during 1980–86
[15], 18 per 100 000 in North Jutland Denmark during 1981–
94 [4], 16 per 100 000 during 1995–2002 [8] and 21 per
100 000 during 2004–07 [16] in Finland, 32 per 100 000 in
Olmsted County, MN, USA during 2003–05 [6], and 22 per
100 000 in England in 2008 [17]. There have been a number of
population-based studies specifically investigating the epidemi-
ology of S. aureus BSI and these are summarized in Table 1
[25–33]. Of note, a number of other population-based studies
have been conducted but have potential overlapping data with
tabulated studies [34–36], or have been restricted to sub-
groups such as MRSA [37–40], location of onset [41], or
included selected age groups [42–48].
A number of important observations may generally be made
based on this body of literature. The incidence of S. aureus BSI
has been increasing in most jurisdictions up until the most
recent decade. The overall contemporary incidence rate of
S. aureus BSI has averaged c.25 per 100 000. In addition, there
has also been considerable variability in overall rates as well as
the proportion that are due to MRSA according to region.
Although rates of MRSA are low in many regions such as the
Scandinavian countries, many other regions worldwide have
observed major increases in MRSA, and there has also been a
shift to increasing rates of community-onset MRSA disease.
Furthermore, where it has emerged, it appears to be a regional
characteristic whether the emergence of MRSA is adding to or
replacing the burden of disease caused by methicillin-suscep-
tible S. aureus.
Streptococcus pneumoniae. Although some studies have
reported CONS or Klebsiella pneumoniae, in general Strepto-
coccus pneumoniae has been the third most frequent cause of
BSI in population-based studies. However, unlike with E. coli
and S. aureus (and most other causes of BSI), immunization
practices for Streptococcus pneumoniae have had a major
influence on its epidemiology in populations. Universal immu-
nization of infants with protein-conjugate pneumococcal
vaccines has led not only to major decreases in childhood
invasive pneumococcal disease but also a decrease in infections
among unvaccinated adults through herd immunity. Hence, the
contemporary epidemiology of Streptococcus pneumoniae BSIs
TABLE 1. Reported and/or estimated incidence rates of Staphylococcus aureus bloodstream infection in non-selected populations
First author, (reference) Population, year
MRSA incidence
per 100 000
MSSA incidence
per 100 000
Total incidence
per 100 000 Comments
Laupland, [25] Multi-national, 2000–08 Community-onset MSSA
incidence was similar among
study regions. Rates of MRSA
and hospital MSSA varied
considerably by region. No
overall change in burden of
S. aureus over time
Canberra, Australia 14.7 21.5 26.3
Calgary, Canada 4.4 24.2 28.6
Victoria, Canada 3.0 18.1 21.1
Sherbrooke, Canada 3.3 18.2 21.5
North Denmark 0.1 30.5 30.6
Copenhagen County, Denmark 0.4 31.8 32.1
Copenhagen City, Denmark 0.5 30.5 31.0
Finland 0.4 19.9 20.3
Sweden 0 23.0 23.0
Overall 1.9 24.2 26.1
Huggan, [26] Canterbury, New Zealand, 1998–2006 0.1 21.5 21.6 Higher socioeconomic status
was associated with lower
rates of BSI
Lyytikainen, [27] Finland, 1995–2001  0.1 14 14 Significant increase over time
(11 to 17 per 100 000). Major
regional variability observed
Tong, [28] Darwin, Australia, 2007/2007 16 49 65 Incidence rate in Aboriginal
population 172 per 100 000 as
compared to 30 per 100 000
for non-Aboriginals
Frimodt-Moller, [29] Denmark, 1957–90 0 20 (in 1990) 20 (in 1990) Progressive increase in rates
from 3 (1957) to 20 (1990)
per 100 000
Collignon, [30] Australia, 1999–2002 9 26 35 Rates estimated from hospital
data
Mc Donald, [31] Northern Ireland (North) and
Republic of Ireland (South), 1999
North 4; South 9 North 16; South 16 North 20.4; South 24.5 Significant variability observed
within study regions
Morgan, [32] Wales, 1996 5.2 12.7 18 Includes isolations from
cerebrospinal fluid; BSI rate is
somewhat lower
Griffiths, [33] England and Wales, 1993–2002 8 (in 2002) 12 (in 2002) 20 (in 2002) Increasing rates observed until
new millennium; males at
much higher risk
BSI, bloodstream infection; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus.
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in populations is closely related to regional immunization
practices.
There is a large body of literature investigating the
population-based epidemiology of bacteraemic or invasive
pneumococcal disease but a review of each of these studies is
beyond the scope of this report. Contemporary (within the
past decade) studies have been conducted in selected child-
hood [49–59] or adult [60–66] age groups in diverse
geographical jurisdictions worldwide. A relatively smaller
number of studies have been conducted in entire populations
in recent years and these are displayed in Table 2 [67–81].
Importantly, most studies investigating serious infections due
to S. pneumoniae have included invasive disease (i.e. those
infections associated with culture from a normally sterile body
site such as blood, cerebrospinal fluid, or other aseptically
obtained deep fluid aspirates). While the majority of invasive
disease is associated with BSI, exact rates of BSI are
not reported and must be inferred or estimated in many
publications.
Others. Although E. coli, S. aureus and Streptococcus pneumoniae
are the most common and typically represent the majority of
all BSIs in a region, CONS, K. pneumoniae, enterococci, b-
haemolytic streptococci, Pseudomonas aeruginosa, yeasts and
other Enterobacteriaceae are other common aetiologies of BSI
and have been the topic of population-based investigations
[6,14,16,17,82–89] A detailed comprehensive review of all of
the published population-based studies of individual causes of
BSI is beyond the scope of this report.
Discussion
Despite the importance of BSI, its overall burden in non-
selected populations has only been defined in a small number
of studies from Europe and North America. Based on these
investigations, an overall average rate of c.140–160 per
100 000 is suggested to occur in populations in high-income
countries. However, there are many determinants that impact
TABLE 2. Contemporary studies of invasive disease and bloodstream infection due to Streptococcus pneumoniae in non-selected
populations
First author
(reference)
Population,
year
Invasive disease
incidence per
100 000
BSI rate or proportion of
isolates in blood Comments
Stephens, [67] Atlanta, USA, 1994–2002 30.2 (1994–99)
13.1 (2002)
95% Protein-conjugate pneumococcal vaccine
licensed in USA in 2000
Rosen, [68] Eight regions in the USA,
1998–2009
19–29.9 (1998–99) vs 11.2–18
(2009)
Not reported Overall reduction in all sites 10.9
per 100 000
Harboe, [69] Denmark, 1938–2007 2.8 (1938–97) 15.7 (1980–90s);
c. 20 (1998–2007)
81% Routine PCV not implemented in Denmark
until 2008
Ingels, [70] Denmark, 2000–2010 19.5 (2000–07)
17.7 (2008–10)
Not reported Increase in non-vaccine serotypes from
11.8 to 13.9 cases per 100 000 during
study periods
Weatherholtz, [71] Navajo Nation, USA, 1995–2006 67 (1995–97)
51 (2004–06)
>98% in children <5 years;
otherwise not reported
Navajo at four-fold increased risk as
compared to general US population
Lacapa, [72] Fort Apache Indian Reserve,
USA, 1991–2006
126 (1991–97)
87 (2001–06)
99% in children; otherwise
not reported
White Mountain Apache children at six-fold
increased risk compared to general US
population
Klemets, [73] Finland, 1995–2002 10.6 9.9 per 100 000 BSI rate related to culturing intensity. Rate
11.0 per 100 000 in most recent study
years
Motlova, [74] Czech Republic, 2000–2006 Range 2.3–4.3 Not reported Incidence rates may be influenced by low
blood culturing rates
Hsieh, [75] Taiwan, 2007 2.6  94% PCV coverage 16% of children under age
5 in 2007
Kellner, [76] Calgary, Canada, 1998–2007 12 89% Routine PCV in 2002; decrease in vaccine
serotypes offset by large serotype-5
outbreak in adults
Einarsdottir, [77] Iceland, 1975–2004 8.3 and 16.7 during the first and
second half of study, respectively
Bruce, [78] Seven circumpolar regions,
1999–2005
19.8 Greenland
14.6 Iceland
16.2 Norway
9.1 Sweden
11.6 Finland
20.6 (pre-PCV) and 15.8
(post-PCV) Alaska
31 (pre-PCV) 21.6 (post-PCV)
Northern Canada
Not reported Indigenous people at four-fold higher risk
in both Alaska and Northern Canada
Andresen, [79] Canberra, Australia, 1998–2000 15.2 Not reported Very high rate observed in children under
2 years of age
Heffernan, [80] New Zealand, 1998–2005 12.4 93% PCV only offered to high-risk infants
during study period
Baggett, [81] Two areas in rural Thailand, 2005–07 – 3.7 per 100 000 (Sa Kaeo)
7.6 per 100 000
(Nakhon Phanom)
Likely underestimate as only hospitalized
patients included
BSI, bloodstream infection; PCV, Protein-conjugate vaccine.
In some jurisdictions, multiple studies have been published from the same population; representative data has been selected from these publications for presentation.
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actual rates within regional populations, not limited to
culturing rates, clinical practices, surveillance ascertainment,
as well as socioeconomic and ethno-cultural influences.
Despite these challenges, it must be recognized that BSI is a
major healthcare problem that is comparable in burden of
disease such as major stroke, acute myocardial infarction and
trauma [5]. Documenting this burden of disease is important
for influencing healthcare and research resources. Population-
based studies establishing the burden of BSI are urgently
needed from other jurisdictions worldwide.
In addition to establishing the occurrence of disease,
population-based studies can provide important information
on the risk factors, detect emerging pathogens, and are the best
means for establishing the effectiveness of preventative inter-
ventions in populations. For example, according to hospital-
based studies, it was previously believed that resistant organ-
isms, such as extended-spectrum b-lactamase-producing En-
terobacteriaceae, were hospital-acquired infections. However,
hospital-based studies are inadequate to explore that issue.
Indeed, when we conducted population-based surveillance
(including hospital and community surveillance) for these
infections, we discovered that the majority were of commu-
nity-onset [90]! Furthermore, when we further studied deter-
minants of these infections, the most important risk factor for
their acquisition was international travel [91]. Whereas clinical
trials are the best means to demonstrate the benefit of vaccines
in demonstrating efficacy in protecting individuals from an
infection, it is surveillance studies such as those included in
Table 2 that are the best means to establish their effectiveness at
reducing the burden of disease in a population.
There are some key methodological features that are
important to emphasize with population-based studies. As
noted in the preceding paragraph, all cases of disease are
identified such that a comprehensive view of an infection can
be established. All cultures performed from outpatients,
emergency departments, and hospitalized patients in both
public and privately funded laboratories must be included.
However, equally as important as identifying all individuals in a
population who fulfil a case definition for a study is excluding
those individuals who are external to the population at risk.
Indeed, patients who are external to a population frequently
have characteristics that are different from those that arise
from within a population, and failure to exclude these cases
will result in an overestimate of disease occurrence as well as
introduce a ‘referral bias’ [13]. Another important aspect is
that because populations at risk are known, age and gender
standardization can be performed to facilitate comparisons
among different regions and time periods. This is of particular
importance when two populations differ significantly in their
demographic profiles because the risk for BSI increases with
advancing age. The value of this, however, is also predicated on
the accuracy of the population denominator data that is
available. The main drawback to population-based studies is
that due to their comprehensive nature, they may be
prohibitively expensive to conduct in many regions, especially
those with multiple independent laboratories. Most of the
regions worldwide that have conducted population-based
studies have been from strong publicly funded healthcare
systems with centralized data or laboratory systems.
In summary, knowledge of the incidence of BSI is important
for establishing its burden. Population-based studies are the
reference standard methods to determine the incidence of an
infectious disease and further studies are needed to establish
the overall incidence of BSI in non-selected populations
worldwide.
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